GTHP (Guided Therapeutics) Payments of Debt: $-0.76 Mil (TTM As of Mar. 2026)


GTHP Guided Therapeutics Inc GTHP
18 GF Score
Price $0.28
! 4 Warning Signs
View Full Analysis

What is Guided Therapeutics Payments of Debt?

Guided Therapeutics GTHP +14.29% 18 Payments of Debt is $-0.76 Mil as of Mar. 2026. GuruFocus rates GTHP with a GF Score™ of 18/100. The stock has 4 warning signs investors should review.

Guided Therapeutics's Payments of Debt for the three months ended in Mar. 2026 was $-0.22 Mil.

Guided Therapeutics's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.76 Mil.

Guided Therapeutics Payments of Debt Related Terms

Guided Therapeutics Payments of Debt Historical Data

* Premium members only.

The historical data trend for Guided Therapeutics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guided Therapeutics Payments of Debt Chart

Guided Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.47 -1.08 -0.82 -0.48 -0.54

Guided Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.22 -0.13 -0.20 -0.22
GTHP
18GF Score
Guided Therapeutics Inc GTHP
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guided Therapeutics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-0.76 Mil mean?
Guided Therapeutics (GTHP) has a Payments of Debt of $-0.76 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Guided Therapeutics and its competitors.
Is Guided Therapeutics' Payments of Debt too high?
Guided Therapeutics' current Payments of Debt is $-0.76 Mil. Overall, Guided Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Guided Therapeutics' Payments of Debt compare to CTSO and IRIX?
Guided Therapeutics' Payments of Debt of $-0.76 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Guided Therapeutics and its competitors. Guided Therapeutics's current Payments of Debt is $-0.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guided Therapeutics stock overvalued right now?
Guided Therapeutics (GTHP) has a current Payments of Debt of $-0.76 Mil. The current Payments of Debt is $-0.76 Mil. Guided Therapeutics' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Guided Therapeutics (GTHP), the current Payments of Debt is $-0.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guided Therapeutics Business Description

Address 5835 Peachtree Corners East, Suite B, Peachtree Corners, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
18GF Score

Get the complete analysis for GTHP

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price